Clinical Trial Update: Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of clofarabine and gemtuzumab ozogamicin for relapsed or refractory acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Clolar (Clofarabine)
• Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Leukemia | Phase 1 | Status: TERMINATED